NCT04708730View on ClinicalTrials.gov

Improving Neuroprotective Strategy for Ischemic Stroke After Thrombectomy Followed by DELP (INSIST-DELP)

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 15, 2021

Primary Completion Date

November 3, 2023

Study Completion Date

February 8, 2024

Conditions
Ischemic Stroke
Interventions
DEVICE

Delipid Extracorporeal Lipoprotein filter from Plasma

As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke

Trial Locations (1)

110016

Department of Neurology, General Hospital of Northern Theater Command, Shenyang

All Listed Sponsors
lead

General Hospital of Shenyang Military Region

OTHER

NCT04708730 - Improving Neuroprotective Strategy for Ischemic Stroke After Thrombectomy Followed by DELP (INSIST-DELP) | Biotech Hunter | Biotech Hunter